Regorafenib, which is known to inhibit the RAS/MAPK, PI3K/Akt/mTOR, and Fos/Jun pathways, has also shown good in vivo and in vitro efficacy against NB cells [139]. The gene discussed is AKT1; the disease is neuroblastoma.